Bristol Myers Squibb (BMY) Acquisitions (2009 - 2026)
Bristol Myers Squibb (BMY) reported Acquisitions of $65.0 million for Q1 2026, down 16.67% year-over-year from $78.0 million in Q1 2025, and down 96.19% on a QoQ basis from $1.7 billion in Q4 2025.
Bristol Myers Squibb (BMY) has 16 years of Acquisitions data on file, last reported at $65.0 million in Q1 2026.
- Quarterly Acquisitions fell 16.67% year-over-year to $65.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $3.9 billion (up 112.95% YoY) and the FY2025 annual result came in at $3.9 billion, down 81.93% from the prior year.
- Acquisitions slipped to $65.0 million in Q1 2026 per BMY's latest filing, from $1.7 billion in the prior quarter.
- Across five years, Acquisitions topped out at $20.1 billion in Q1 2024 and bottomed at $47.0 million in Q4 2024.
- The 5-year median for Acquisitions is $348.0 million (2024), against an average of $1.8 billion.
- The widest annual swing landed in 2024, when Acquisitions surged 25608.97%; it then plunged 99.61% in 2025.
- Tracing BMY's Acquisitions over 5 years: stood at $116.0 million in 2022, then surged by 400.86% to $581.0 million in 2023, then slumped by 91.91% to $47.0 million in 2024, then surged by 3531.91% to $1.7 billion in 2025, then plunged by 96.19% to $65.0 million in 2026.
- Per Business Quant, the three latest BMY Acquisitions figures stand at $65.0 million (Q1 2026), $1.7 billion (Q4 2025), and $1.9 billion (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Acquisitions (Qtr) |
|---|---|---|---|---|---|
| 1 | Novartis Ag | 107,124,802.25 Bn | 107,124,802.25 Bn | - | - |
| 2 | Eli Lilly | 969.00 Bn | 963.72 Bn | 16.22 Bn | - |
| 3 | Johnson & Johnson | 539.46 Bn | 517.41 Bn | 15.96 Bn | - |
| 4 | AbbVie | 376.92 Bn | 367.57 Bn | 10.78 Bn | - |
| 5 | Merck | 285.00 Bn | 279.35 Bn | 12.09 Bn | 8.78 Bn |
| 6 | Amgen | 177.58 Bn | 165.55 Bn | 5.87 Bn | - |
| 7 | Gilead Sciences | 163.22 Bn | 155.50 Bn | 5.52 Bn | 109.00 Mn |
| 8 | Pfizer | 145.86 Bn | 133.09 Bn | -1.21 Bn | - |
| 9 | Bristol Myers Squibb | 111.90 Bn | 101.44 Bn | 8.07 Bn | 65.00 Mn |
| 10 | Gsk | 88.34 Bn | 83.66 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 65.00 Mn |
| Dec 31, 2025 | 1.71 Bn |
| Sep 30, 2025 | 1.87 Bn |
| Jun 30, 2025 | 285.00 Mn |
| Mar 31, 2025 | 78.00 Mn |
| Dec 31, 2024 | 47.00 Mn |
| Sep 30, 2024 | 348.00 Mn |
| Jun 30, 2024 | 1.37 Bn |
| Mar 31, 2024 | 20.05 Bn |
| Dec 31, 2023 | 581.00 Mn |
| Sep 30, 2023 | 326.00 Mn |
| Jun 30, 2023 | 184.00 Mn |
| Mar 31, 2023 | 78.00 Mn |
| Dec 31, 2022 | 116.00 Mn |
| Sep 30, 2022 | 3.26 Bn |
| Jun 30, 2022 | 467.00 Mn |
| Mar 31, 2022 | 442.00 Mn |
| Dec 31, 2021 | 152.00 Mn |
| Sep 30, 2021 | 1.06 Bn |
| Jun 30, 2021 | 366.00 Mn |
| Mar 31, 2021 | 35.00 Mn |
| Dec 31, 2020 | 12.35 Bn |
| Sep 30, 2020 | 291.00 Mn |
| Jun 30, 2020 | 377.00 Mn |
| Mar 31, 2020 | 68.00 Mn |
| Dec 31, 2019 | 24.72 Bn |
| Sep 30, 2019 | 9.00 Mn |
| Jun 30, 2019 | 34.00 Mn |
| Mar 31, 2019 | 15.00 Mn |
| Dec 31, 2018 | 1.16 Bn |
| Sep 30, 2018 | 45.00 Mn |
| Jun 30, 2018 | 834.00 Mn |
| Mar 31, 2018 | 336.00 Mn |
| Dec 31, 2017 | 54.00 Mn |
| Sep 30, 2017 | 353.00 Mn |
| Jun 30, 2017 | 207.00 Mn |
| Mar 31, 2017 | 112.00 Mn |
| Dec 31, 2016 | 48.00 Mn |
| Sep 30, 2016 | 44.00 Mn |
| Jun 30, 2016 | 259.00 Mn |
| Mar 31, 2016 | 8.00 Mn |
| Dec 31, 2015 | 219.00 Mn |
| Sep 30, 2015 | 37.00 Mn |
| Dec 31, 2014 | 6.00 Mn |
| Jun 30, 2014 | 192.00 Mn |
| Mar 31, 2014 | 21.00 Mn |
| Sep 30, 2012 | 5.04 Bn |
| Mar 31, 2012 | 2.49 Bn |
| Dec 31, 2011 | 50.00 Mn |
| Sep 30, 2009 | 2.23 Bn |